HEXALEN
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEXALEN is an oral small-molecule anticancer agent approved in 1990 for treatment of ovarian cancer and other malignancies. The drug is administered as a capsule and represents a legacy chemotherapy option in the oncology market. Mechanism of action details are not publicly documented in available sources.
LOE Approaching
As a mature small-molecule product approaching loss of exclusivity, team size is likely stable or contracting with focus on defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HEXALEN offers limited career growth given its mature lifecycle and approaching loss of exclusivity. Roles are primarily defensive and focused on maximizing remaining market share and managing generic transition.
Brand Manager (Legacy)Field Sales Representative
Worked on HEXALEN at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.